Baseline values in the four blinded vertebroplasty trials which have been published
| Trial | Kallmes et al 8 | Buchbinder et al 19 | VERTOS4 | VAPOUR |
| Enrolment (no) | 131 | 78 | 176 | 120 |
| Inpatients | 0 | Not reported | 0 | 59% |
| Fracture duration range | <12 months | <12 months | <12 weeks | <6 weeks |
| Mean fracture duration (IQR) weeks | 22.5 (10–36) | 11.7 (3.8–13) | 6.1 (4–7.4) | 2.6 (1–3) |
| Fracture duration ≤3/52 | 0 | <20% | <20% | 79% |
| Mean pain score | 7.0 (1.9) | 7.3 (2.2) | 7.8 (1.5) | 8.6 (1.2) |
| T-score mean (SD) | Not reported | Not reported | −2.4 (1.0) | −4.3 (1.0) |
| PMMA volume cc (SD) | 2.6 | 2.8 (1.2) | 5.1 (1.8) | 7.5 (2.8) |
Mean fracture duration for VERTOS4 derives from conference proceedings. Mean fracture duration data for Buchbinder et al and Kallmes et al are derived from Staples et al. PMMA volume Kallmes et al is via author correspondence. The VAPOUR trial is clinically heterogeneous to the other trials.